Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

about

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

Item

http://www.wikidata.org/entity/Q52643700

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@en

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@nl

type

Item

label

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@en

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@nl

prefLabel

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@en

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@nl

P1476

Novel Somatostatin Receptor Ligands Therapies for Acromegaly.

@en

P2093

Roberto Salvatori

http://www.w3.org/2001/XMLSchema#string

Rosa Maria Paragliola

http://www.w3.org/2001/XMLSchema#string

P2860

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly

Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors

Rationale for the use of somatostatin analogs as antitumor agents

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FENDO.2018.00078

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29563895

http://www.w3.org/2001/XMLSchema#string

P932

5845985

http://www.w3.org/2001/XMLSchema#string